12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known as biologics to cheaper near-copies of the medications, a move that will save the province hundreds of millions of dollars in the coming years.

The major policy change in favour of the less-expensive versions, called biosimilars, will take effect by next summer and is expected to save $227-million to $380-million over the next four years. 

Alberta will become the second province after British Columbia to stop covering some of the brand-name biologic drugs that have driven significant increases in prescription-drug spending across the country.

Read Globe and Mail article